Pharmaceutical compounding of orphan active ingredients in Belgium: how community and hospital pharmacists can address the needs of patients with rare diseases

Abstract Background Pharmaceutical compounding of orphan active ingredients can offer cost-effective treatment to patients when no other drug product is available for a rare disease or during periods of drug product shortages. Additionally, it allows customized therapy for patients with rare disease...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	Orphanet Journal of Rare Diseases
المؤلفون الرئيسيون:	V. Vanhoorne, E. Peeters, I. Van Tongelen, K. Boussery, E. Wynendaele, B. De Spiegeleer, J. P. Remon, C. Vervaet
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	BMC 2019-08-01
الموضوعات:	Rare diseases Orphan active ingredients Pharmaceutical compounding
الوصول للمادة أونلاين:	http://link.springer.com/article/10.1186/s13023-019-1154-x

مواد مشابهة

Expenditure trends of orphan drugs in Serbia: 8-Year analysis of orphan drug market in Serbia
حسب: Pejčić Ana V., وآخرون
منشور في: (2016-01-01)

Public spending on orphan medicines: a review of the literature
حسب: Margit Gombocz, وآخرون
منشور في: (2020-12-01)

EMA approved orphan medicines since the implementation of the orphan legislation
حسب: Eveliina Hahl, وآخرون
منشور في: (2025-06-01)

Analysis of patient access to orphan drugs in Turkey
حسب: Güvenç Koçkaya, وآخرون
منشور في: (2021-02-01)

THE MANUFACTURING OF PHARMACEUTICAL INGREDIENTS IN RUSSIAN FEDERATION: THE CRISIS AT THE TURN OF XX TO XXI CENTURIES
حسب: E. V. Denisova
منشور في: (2019-01-01)

Practice of the Qualification and Recognition for Orphan Drugs in the World and its Inspiration
حسب: ZHU Xiaohong, وآخرون
منشور في: (2022-07-01)

Continuous-Flow Chemistry and Photochemistry for Manufacturing of Active Pharmaceutical Ingredients
حسب: Pavlína Horáková, وآخرون
منشور في: (2022-12-01)

Current Problems in Provision of Orphan Drugs and Ways to Solve Them
حسب: Alexei S. Kolbin, وآخرون
منشور في: (2016-09-01)

Pharmacists are initiators in palliative care for patients with rare diseases
حسب: M. Dooms
منشور في: (2023-06-01)

Trends in orphan medicinal products approvals in the European Union between 2010–2022
حسب: Luísa Bouwman, وآخرون
منشور في: (2024-02-01)

Visual Research of Global Orphan Drug from a Bibliometric Perspective
حسب: Wen X, وآخرون
منشور في: (2025-05-01)

« Orphans ». Hyponym for rare diseases, but not so ultra-rare.
حسب: Nor El Houda KHELIF, وآخرون
منشور في: (2025-06-01)

Active pharmaceutical ingredients in dermatological medicines of Ukrainian pharmaceutical market
حسب: I. O. Vlasenko, وآخرون
منشور في: (2019-03-01)

Cross-national comparative study of orphan drug policies in Saudi Arabia, the United States, and the European Union
حسب: Bander Balkhi, وآخرون
منشور في: (2023-09-01)

Patient access to orphan drugs in France
حسب: Marion Bourdoncle, وآخرون
منشور في: (2019-02-01)

Ionic Liquids as Tools to Incorporate Pharmaceutical Ingredients into Biopolymer-Based Drug Delivery Systems
حسب: Paula Berton, وآخرون
منشور في: (2023-02-01)

Editorial: Medicinal chemistry of active pharmaceutical ingredients of drug products
حسب: Mohd Imran, وآخرون
منشور في: (2024-04-01)

Therapiekosten von Orphan Drugs vor und nach Einführung des AMNOG
حسب: Lukas Maag MSc, وآخرون
منشور في: (2022-10-01)

Development of orphan drugs for rare diseases
حسب: Han-Wook Yoo
منشور في: (2024-07-01)

Features of intellectual property protection mechanisms on the example of orphan drugs circulation
حسب: D. S. Yurochkin, وآخرون
منشور في: (2022-01-01)

Current Status and Prospect of Orphan Drugs for Rare Skin Diseases in China
حسب: ZHANG Shan, وآخرون
منشور في: (2023-04-01)

Orphan drug policy analysis in China
حسب: Meilin Liu, وآخرون
منشور في: (2024-06-01)

An improved procedure for synthesis of lenalidomide as an active pharmaceutical ingredient
حسب: Elaheh Ataollahi, وآخرون
منشور في: (2025-09-01)

Brazilian national production of active pharmaceutical ingredients: regulatory and strategic framework
حسب: MARLON DANIEL L. TONINI, وآخرون
منشور في: (2023-12-01)

Generic orphan drug substitution: a critical analysis of global practices and Saudi Arabia’s perspective
حسب: Yousif S. Alakeel, وآخرون
منشور في: (2024-04-01)

Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes
حسب: Liz Morrell, وآخرون
منشور في: (2017-08-01)

A comparative study of orphan drug prices in Europe
حسب: Katherine Eve Young, وآخرون
منشور في: (2017-01-01)

Occurrence and toxicological assessment of selected active pharmaceutical ingredients in effluents of pharmaceutical manufacturing plants and wastewater treatment plants in Kampala, Uganda
حسب: R. Kayiwa, وآخرون
منشور في: (2022-04-01)

Improving the Physicochemical and Biopharmaceutical Properties of Active Pharmaceutical Ingredients Derived from Traditional Chinese Medicine through Cocrystal Engineering
حسب: Danyingzi Guan, وآخرون
منشور في: (2021-12-01)

Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen
حسب: Viviana Giannuzzi, وآخرون
منشور في: (2017-04-01)

Simple, Accurate and Multianalyte Determination of Thirteen Active Pharmaceutical Ingredients in Polypills by HPLC-DAD
حسب: Barbara Żuromska-Witek, وآخرون
منشور في: (2022-12-01)

Binary Mixtures of Some Active Pharmaceutical Ingredients with Fatty Alcohols—The Criteria of Successful Eutectic Formation and Dissolution Improvement
حسب: Songhee Jin, وآخرون
منشور في: (2020-11-01)

REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS
حسب: Andrey Vladislavovich Pavlysh, وآخرون
منشور في: (2015-09-01)

Current Situation, Trend, and Opportunity of Applying Blockchain to the Supply Chain of Orphan Drugs
حسب: LI Wenyan, وآخرون
منشور في: (2025-01-01)

Crowd Funding for Orphan Drugs: The Case of Baby Pia
حسب: Wim Pinxten
منشور في: (2021-12-01)

Variables affecting pricing of orphan drugs: the Italian case
حسب: Claudio Jommi, وآخرون
منشور في: (2021-10-01)

Just Treatment of Orphans as Viewed by Quran Interpreters
حسب: Muhammad Moradi, وآخرون
منشور في: (2020-12-01)

DEVELOPMENT AND VALIDATION OF METHOD OF QUANTITATIVE DETERMINATION OF RESIDUAL ORGANIC SOLVENTS IN INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT WITH GC-FID
حسب: E. V. Butina, وآخرون
منشور في: (2019-01-01)

International comparison of availability for orphan drugs: focused on approved orphan drugs in South Korea
حسب: Eun Young Shin, وآخرون
منشور في: (2024-12-01)

Quantifying the persisting orphan-drug shortage public health crisis in the United States
حسب: Szymon Jarosławski, وآخرون
منشور في: (2017-01-01)